Minerva Neurosciences, Inc (NERV) News

Minerva Neurosciences, Inc (NERV): $4.95

0.25 (+5.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 468

in industry

Filter NERV News Items

NERV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NERV News From Around the Web

Below are the latest news stories about Minerva Neurosciences Inc that investors may wish to consider to help them evaluate NERV as an investment opportunity.

Insider Selling: Minerva Neurosciences, Inc. (NASDAQ:NERV) Director Sells 55,635 Shares of Stock

Minerva Neurosciences, Inc. (NASDAQ:NERV) Director David Kupfer sold 55,635 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $0.88, for a total transaction of $48,958.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through []

Transcript Daily | December 6, 2021

Minerva Neurosciences (NASDAQ:NERV) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical companys stock. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and []

Dakota Financial News | December 6, 2021

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Upgraded by Zacks Investment Research

Minerva Neurosciences (NASDAQ:NERV) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $1.00 target price on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 7.99% from the companys current []

Transcript Daily | December 5, 2021

Minerva Neurosciences (NASDAQ:NERV) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central []

Dakota Financial News | December 5, 2021

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 1, 2021

Zacks Investment Research Downgrades Minerva Neurosciences (NASDAQ:NERV) to Hold

Zacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat [] The post Zacks Investment Research Downgrades Minerva Neurosciences (NASDAQ:NERV) to Hold appeared first on ETF Daily News .

ETF Daily News | November 27, 2021

Minerva Neurosciences (NASDAQ:NERV) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $1.25 target price on the biopharmaceutical company’s stock. According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development […]

Dakota Financial News | November 25, 2021

Minerva Neurosciences (NASDAQ:NERV) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research downgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to []

Transcript Daily | November 24, 2021

Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2021

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2021. Roluperidone Update On November 3, 2021, the Company announced that the U. S. Food and Drug Administration (FDA) denied

Yahoo | November 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4566 seconds.